Abstract:In the proposed intelligent biosensing drug‐induced cardiotoxicity assessment platform, the cardiomyocytes are treated with non‐cardiotoxic or cardiotoxic drugs to obtain mechanical beating signals. The beating signals are converted into image representations by phase space reconstruction and analyzed by convolutional neural network to identify the cardiotoxicity of drugs. Drug‐induced cardiotoxicity often leads to patient deaths and drug recalls. Interdigitated electrode (IDE)‐based cellular impedance detection instrument has been integrated with intelligent algorithms to screen cardiotoxicity based on cardiomyocytes. These intelligent biosensing systems generally employ traditional machine learning methods to assess drug‐induced cardiotoxicity by analyzing cardiomyocytes mechanical beating signals. However, modern deep learning methods with robustness and flexibility have not been integrated in IDE‐based platform to screen cardiotoxicity. Here, for the first time, we implemented deep convolutional neural network (CNN) to analyze cardiomyocytes mechanical beating signals for cardiotoxicity assessment. This method can eliminate the feature engineering procedures, such as manual design and extraction of signal features required by traditional machine learning methods. To facilitate two‐dimensional (2‐D) CNN analysis, we utilized phase space reconstruction to convert one‐dimensional beating signals into 2‐D image representations as well as take into account nonlinear dynamic information. The phase space reconstruction‐assisted convolutional neural network (PSRCNN) is capable of accurately categorizing drug‐induced cardiotoxicities and predicting cardiotoxicity levels. It obtains accuracies ranging from 0.82 to 0.99 when recognizing the cardiotoxicity of newly developed drugs, which are represented by drugs that are not used during model training. Furthermore, we explore in depth to compare the performance of CNN with other traditional machine learning methods. The PSRCNN method can achieve higher accuracies when compared to other methods. The PSRCNN‐based biosensing platform is highly potential in improving the efficiency and accuracy of high‐throughput screening of newly developed drugs for cardiotoxicity during drug discovery.

Enhanced drug classification using machine learning with multiplexed cardiac contractility assays

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Multi-labeled Neural Network Model for Automatically Processing Cardiomyocyte Mechanical Beating Signals in Drug Assessment.

CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

A stacking ensemble machine learning model for evaluating cardiac toxicity of drugs based on in silico biomarkers

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays

An intelligent biosensing platform using phase space reconstruction‐assisted convolutional neural network for drug‐induced cardiotoxicity assessment

Advanced Cardiovascular Toxicity Screening: Integrating Human iPSC-Derived Cardiomyocytes with In Silico Models

Industrialization of three-dimensional hiPSC-cardiac microtissues for high-throughput cardiac safety and drug discovery screening

iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity

A Comprehensive Cardiotoxicity Assay by Combining High-Throughput Multiple Ion Channel Screening with Human Cardiomyocyte-Based Action Potential Validation

Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes

Semi-Supervised Learning to Boost Cardiotoxicity Prediction by Mining a Large Unlabeled Small Molecule Dataset

Cardiotoxicity Assessment through a Polymer‐Based Cantilever Platform: An Integrated Electro‐Mechanical Screening Approach

High-Throughput Assessment Of Drug Cardiac Safety Using A High-Speed Impedance Detection Technology-Based Heart-On-A-Chip

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.